Age, Biography and Wiki

A. Mark Richards (Arthur Mark Richards) was born on 1 May, 1955 in Invercargill, New Zealand, is a researcher. Discover A. Mark Richards's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is He in this year and how He spends money? Also learn how He earned most of networth at the age of 68 years old?

Popular As Arthur Mark Richards
Occupation Physician · academic · medical researcher
Age 69 years old
Zodiac Sign Taurus
Born 1 May 1955
Birthday 1 May
Birthplace Invercargill, New Zealand
Nationality New Zealand

We recommend you to check the complete list of Famous People born on 1 May. He is a member of famous researcher with the age 69 years old group.

A. Mark Richards Height, Weight & Measurements

At 69 years old, A. Mark Richards height not available right now. We will update A. Mark Richards's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.

Physical Status
Height Not Available
Weight Not Available
Body Measurements Not Available
Eye Color Not Available
Hair Color Not Available

Dating & Relationship status

He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.

Family
Parents Not Available
Wife Not Available
Sibling Not Available
Children Not Available

A. Mark Richards Net Worth

His net worth has been growing significantly in 2022-2023. So, how much is A. Mark Richards worth at the age of 69 years old? A. Mark Richards’s income source is mostly from being a successful researcher. He is from New Zealand. We have estimated A. Mark Richards's net worth , money, salary, income, and assets.

Net Worth in 2023 $1 Million - $5 Million
Salary in 2023 Under Review
Net Worth in 2022 Pending
Salary in 2022 Under Review
House Not Available
Cars Not Available
Source of Income researcher

A. Mark Richards Social Network

Instagram
Linkedin
Twitter
Facebook
Wikipedia
Imdb

Timeline

2009

In 2009, Richards became the inaugural director of the Cardiovascular Research Institute at the National University of Singapore whilst continuing part-time retention of his New Zealand appointments. He has been deputy director of the National University Heart Centre Singapore (NUHCS) since 2021.

1995

Richards was awarded a personal chair in medicine by the University of Otago in 1995. He was deputy head of the Department of Medicine at the University of Otago, Christchurch, in 1998, and head of department from 2002 to 2003. From 1993 to 1997, he directed the FRACP Part 1 Registrar Training Programme (Christchurch) and was an examiner for FRACP clinical examinations. He was admitted to the fellowship of the Royal College of Physicians (FRCP) in 2008.

Richards was programme director of the New Zealand Health Research Council (HRC) programme grants for serial cardiovascular HRC research programmes continuously for 24 years from 1995 to 2019. In 1997, he was appointed to the National Heart Foundation chair of cardiovascular studies. He founded and assumed chairmanship of the Christchurch Cardioendocrine Research Group, University of Otago, Christchurch, which later became the Christchurch Heart Institute in 2012.

1990

Richards leads ongoing research aimed at refining the clinical applications and beneficial actions of the natriuretic peptides. He has investigated the effect of atrial fibrillation on the diagnostic and prognostic performance of NT-proBNP in suspected heart failure. In the mid-1990s, Richards pioneered human clinical studies of neprilysin inhibition, important in metabolism of the NPs. His group has studied the integrated haemodynamic, endocrine and renal effects of human ANP analogues selected for exclusive vasodilatory or diuretic activities in experimental heart failure laying the path for possible precision peptide therapy in heart failure. His group has demonstrated the beneficial integrated hemodynamic, endocrine, and renal effects of phosphodiesterase-9 inhibition (PDE9-I; which specifically impedes breakdown of the 2nd messenger, cGMP generated by the natriuretic peptides) in experimental HF. Results support PDE9's role in HF pathophysiology and implies that its inhibition could possibly be a novel anti-heart failure therapy.

1988

Richards was appointed as a clinical lecturer at Christchurch School of Medicine, University of Otago, in 1988, where he became a professor in medicine in 1995. Since 2009, he has been professor of cardiology at the National University of Singapore, and a professor (joint faculty) in the Department of Biochemistry at National University Singapore as of 2010, and has also been an associate faculty member at the Genome Institute of Singapore since then.

1978

Richards completed his MB ChB at the University of Otago in 1978. He was admitted as FRACP in Internal Medicine by the Royal Australasian College of Physicians in 1984. He graduated Doctor of Medicine (MD) with distinction in 1986, PhD in medicine in 1993 and Doctor of Science (DSc), with a thesis titled The cardiac natriuretic peptides – from bench to bedside, in 2000 from the University of Otago. The Royal College of Physicians admitted him as FRCP in 2008. In 2019, he graduated with a Bachelor of Arts degree in history from Massey University, New Zealand.

1955

Arthur Mark Richards (born 1 May 1955) is a New Zealand physician, academic and medical researcher. He is a professor of cardiology and director of the Cardiovascular Research Institute at the National University of Singapore, and a professor of medicine and founder of the Christchurch Heart Institute at the University of Otago, Christchurch, New Zealand, where he holds the National Heart Foundation (NZ) Chair of Cardiovascular Studies.